Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/173759
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Roger, Albert | - |
dc.contributor.author | Malet, Alfons | - |
dc.contributor.author | Moreno, Victoria | - |
dc.contributor.author | Parra, Antonio | - |
dc.contributor.author | Gutierrez, Diego | - |
dc.contributor.author | Lleonart Bellfill, Ramón | - |
dc.contributor.author | Moreno, Francisco | - |
dc.contributor.author | Valero, Antonio | - |
dc.contributor.author | Navarro, Begoña | - |
dc.contributor.author | Hinojosa, Belén | - |
dc.contributor.author | Justicia, José L. | - |
dc.date.accessioned | 2021-02-09T09:36:19Z | - |
dc.date.available | 2021-02-09T09:36:19Z | - |
dc.date.issued | 2020-01-01 | - |
dc.identifier.uri | http://hdl.handle.net/2445/173759 | - |
dc.description.abstract | Aim: Evaluate the effectiveness and safety of immunotherapy with Acarovac Plus((R)) in a 1-year prospective multicentered real-life study. Methods: A total of 118 adults with allergic rhinitis sensitized to Dermatophagoides received subcutaneous immunotherapy with Acarovac Plus. Treatment outcomes were evaluated at baseline, 6 months and 1 year after treatment initiation. Primary end point was the evolution of the combined symptom and medication score. Secondary end points included other effectiveness outcomes and measurement of product tolerability. Results: Acarovac Plus induced significant improvements in primary and secondary end points after 6 months compared with baseline. These differences persisted after 1 year of treatment (p < 0.001; baseline vs 1 year): combined symptom and medication score (1.60 vs 0.79). No serious adverse events were recorded. Conclusion: Acarovac Plus for 1 year was effective and well tolerated in a real-life setting. | - |
dc.format.extent | 10 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | Future Medicine Ltd. | - |
dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.2217/imt-2019-0205 | - |
dc.relation.ispartof | Immunotherapy, 2020, vol. 12, num. 1, p. 53-62 | - |
dc.relation.uri | https://doi.org/10.2217/imt-2019-0205 | - |
dc.rights | cc by-nc-nd (c) Roger et al., 2020 | - |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/3.0/es/ | - |
dc.source | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) | - |
dc.subject.classification | Àcars | - |
dc.subject.classification | Rinitis | - |
dc.subject.other | Mites | - |
dc.subject.other | Rhinitis | - |
dc.title | Real-life effect of a microcrystalline tyrosine adjuvanted mite immunotherapy in patients with allergic rhinitis | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.date.updated | 2021-02-08T10:12:28Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.pmid | 31910695 | - |
Appears in Collections: | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
RogerA.pdf | 875.13 kB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License